Global Tuberculosis Report -- 2012.pdf

More documents

Recommendations

Info

WHO SOUTH-EAST ASIA REGIONPopulation 2011 1 830 millionWHO MEMBER STATES 11Estimates of TB burden a 2011 NUMBER (thousands)RATE (per 100 000 population)Mortality (excludes HIV+TB) 480 (350–630) 26 (19–34)Prevalence (includes HIV+TB) 5 000 (3 800–6 300) 271 (206–344)Incidence (includes HIV+TB) 3 500 (3 200–3 700) 189 (176–203)Incidence (HIV+TB) 140 (120–170) 7.7 (6.4–9.1)Case detection, all forms (%) 62 (58–66)TB case notifications 2011NEW CASES (%) RETREATMENT CASES (%)Smear-positive 1 067 367 (53) Relapse 135 650 (39)Smear-negative 598 800 (30) Treatment after failure 23 252 (6.6)Smear-unknown/not done 0 (0) Treatment after default 76 666 (22)Extrapulmonary 333 993 (17) Other 115 636 (33)Other 2 878 (
WHO WESTERN PACIFIC REGIONPopulation 2011 1 809 millionWHO MEMBER STATES 27OTHER COUNTRIES AND TERRITORIES 9Estimates of TB burden a 2011 NUMBER (thousands) RATE (per 100 000 population)Mortality (excludes HIV+TB) 130 (100–150) 6.9 (5.7–8.3)Prevalence (includes HIV+TB) 2 500 (2 200–2 800) 138 (123–154)Incidence (includes HIV+TB) 1 700 (1 500–1 800) 92 (84–100)Incidence (HIV+TB) 36 (31–42) 2 (1.7–2.3)Case detection, all forms (%) 81 (75–89)TB case notifications 2011NEW CASES (%) RETREATMENT CASES (%)Smear-positive 576 044 (44) Relapse 50 841 (60)Smear-negative 630 219 (49) Treatment after failure 3 967 (4.7)Smear-unknown/not done 17 435 (1.3) Treatment after default 3 371 (4.0)Extrapulmonary 68 949 (5.3) Other 25 919 (31)Other 2 708 (
Page 2 and 3:
GLOBALTUBERCULOSISREPORT2012
Page 4 and 5:
ContentsAbbreviationsivAcknowledgem
Page 6 and 7:
AcknowledgementsThis report on glob
Page 8 and 9:
WHO Western Pacific RegionShalala A
Page 10 and 11:
Executive SummaryThe World Health O
Page 12 and 13:
CHAPTER 1IntroductionBOX 1.1Basic f
Page 14 and 15:
TABLE 1.1 Targets for the scale-up
Page 16 and 17:
TABLE 1.2 Reporting of data in the
Page 18 and 19:
BOX 2.1Uncertainty in estimates of
Page 20 and 21:
TABLE 2.2 Estimated burden of disea
Page 22 and 23:
FIGURE 2.5 Estimated TB incidence r
Page 24 and 25:
FIGURE B2.2.1Reporting of notificat
Page 26 and 27:
FIGURE 2.8Estimated TB incidence ra
Page 28 and 29:
FIGURE 2.11 Countries (in blue) for
Page 30 and 31:
FIGURE 2.12 Trends in estimated TB
Page 32 and 33:
● producing and widely disseminat
Page 34 and 35:
FIGURE 2.16 Progress in global cove
Page 36 and 37:
BOX 2.6Efforts by the Task Force to
Page 38 and 39:
CHAPTER 3TB case notificationsand t
Page 40 and 41:
BOX 3.1 1Definitions of TB casesDef
Page 42 and 43:
TABLE 3.3 Contribution of public-pr
Page 44 and 45:
BOX 3.4Integrating community-based
Page 46 and 47:
TABLE 3.4 Estimates of the case det
Page 48 and 49:
TABLE 3.5 Treatment success for new
Page 50 and 51:
CHAPTER 4Drug-resistant TBKEY FACTS
Page 52 and 53:
FIGURE 4.2 Percentage of new TB cas
Page 54 and 55:
BOX 4.1Frequencies of resistance to
Page 56 and 57:
FIGURE 4.6 Number of MDR-TB cases e
Page 58 and 59:
FIGURE 4.7Notified cases of MDR-TB
Page 60 and 61:
egimens globally, providing more su
Page 62 and 63:
5.1 Funding for TB care and control
Page 64 and 65:
TABLE 5.2 NTP budgets, available fu
Page 66 and 67:
FIGURE 5.5Trends in domestic and do
Page 68 and 69:
FIGURE 5.6Domestic funding as a per
Page 70 and 71:
FIGURE 5.8Cost per TB patient succe
Page 72 and 73:
FIGURE 5.10 Total cost and unit cos
Page 74 and 75:
● The 14 countries not included i
Page 76 and 77:
on public health by an external Exp
Page 78 and 79:
evised as a result of the introduct
Page 80 and 81:
TABLE 6.2 Incorporation of WHO poli
Page 82 and 83:
FIGURE 6.3The Supranational Referen
Page 84 and 85:
of TB disease by 65%, irrespective
Page 86 and 87:
FIGURE 7.3Percentage of TB patients
Page 88 and 89:
BOX 7.1Accelerating progress in pro
Page 90 and 91:
TABLE 7.2 Assumptions used to estim
Page 92 and 93:
FIGURE 8.1 The development pipeline
Page 94 and 95: sputum specimens and TB isolates fr
Page 96 and 97: cal trial sites and building labora
Page 98: new TB vaccine candidate. A Phase I
Page 102 and 103: This annex explains the methods tha
Page 104 and 105: 2011. On average, 15 data points we
Page 106 and 107: may suffer from biases. These biase
Page 108 and 109: TABLE A1.3Parameter estimates used
Page 110 and 111: 5. Estimates of TB prevalence, 1990
Page 112: the Republic of Moldova, Romania, t
Page 116 and 117: AFGHANISTANPopulation 2011 32 milli
Page 118 and 119: BRAZILPopulation 2011 197 millionHI
Page 120 and 121: CHINAPopulation 2011 1 348 millionH
Page 122 and 123: ETHIOPIAPopulation 2011 85 millionH
Page 124 and 125: INDONESIAPopulation 2011 242 millio
Page 126 and 127: MOZAMBIQUEPopulation 2011 24 millio
Page 128 and 129: NIGERIAPopulation 2011 162 millionH
Page 130 and 131: PHILIPPINESPopulation 2011 95 milli
Page 132 and 133: SOUTH AFRICAPopulation 2011 50 mill
Page 134 and 135: UGANDAPopulation 2011 35 millionHIG
Page 136 and 137: VIET NAMPopulation 2011 89 millionH
Page 138: ANNEX 3Regional profiles
Page 141 and 142: WHO REGION OF THE AMERICASPopulatio
Page 143: WHO EUROPEAN REGIONPopulation 2011
Page 148 and 149: SUMMARY BY WHO REGIONTable A4.1 Est
Page 150 and 151: MORTALITY (EXCLUDING HIV) PREVALENC
Page 152 and 153: NEW AND RELAPSENOTIFICATION RATE aY
Page 154 and 155: -% OF TB PATIENTS WITHKNOWN HIV STA
Page 156 and 157: AFRICAN REGIONTable A4.1 Estimates
Page 162 and 163: INCIDENCE (INCLUDING HIV) INCIDENCE
Page 164 and 165: NEW AND RELAPSENOTIFICATION RATE aY
Page 166 and 167: NEW AND RELAPSENOTIFICATION RATE a1
Page 168 and 169: TREATMENT SUCCESS (%) a1995-2010YEA
Page 174 and 175: -% OF TB PATIENTS WITHKNOWN HIV STA
Page 176 and 177: YEARTOTALCONFIRMEDCASES OFMDR-TB aE
Page 178 and 179: MALEYEAR 0-14 15-24 25-34 35-44 45-
Page 180 and 181: REGION OF THE AMERICASTable A4.1 Es
Page 186 and 187: INCIDENCE (INCLUDING HIV) INCIDENCE
Page 192 and 193: % OF COHORTTREATMENT SUCCESS (%) a1
Page 194 and 195:
% OF COHORTTREATMENT SUCCESS (%) a1
Page 196 and 197:
Page 198 and 199:
-% OF TB PATIENTS WITHKNOWN HIV STA
Page 200 and 201:
YEARTOTALCONFIRMEDCASES OFMDR-TB aE
Page 202 and 203:
MALEFEMALEYEAR 0-14 15-24 25-34 35-
Page 204 and 205:
EASTERN MEDITERRANEAN REGIONTable A
Page 206 and 207:
MORTALITY (EXCLUDING HIV) PREVALENC
Page 208 and 209:
INCIDENCE (INCLUDING HIV) INCIDENCE
Page 210 and 211:
NEW AND RELAPSENOTIFICATION RATE a1
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
EUROPEAN REGIONTable A4.1 Estimates
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
SOUTH-EAST ASIA REGIONTable A4.1 Es
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258:
SMEAR LABS % OF SMEARPER 100K LABS
Page 261 and 262:
Estimates of mortality, prevalence
Page 263 and 264:
YEARPOPULATION(MILLIONS)MORTALITY (
Page 265 and 266:
YEARPOPULATION(MILLIONS)INCIDENCE (
Page 267 and 268:
YEARPOPULATION(MILLIONS)INCIDENCE (
Page 269 and 270:
Page 271 and 272:
TREATMENT SUCCESS (%) a1995-2010YEA
Page 273 and 274:
TREATMENT SUCCESS (%) a1995-2010YEA
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
SMEAR LABS % OF SMEARPER 100K LABS
show all

Global Tuberculosis Report -- 2012.pdf

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?